Report Description

The global lung cancer genomic testing market is still at an early stage and is anticipated to witness a steady CAGR  in the forecast period, 2023-2027. Factors such as growing awareness and adoption of lung cancer genomic testing and the high prevalence of lung cancer worldwide are the primary drivers for the global lung cancer genomic testing market. The other factors include the high-end investments by the private and public players to facilitate research and development activities to cure lung cancer and the favorable government policies and campaigns to create awareness about different cancer types among consumers. Also, the rapid shift of the healthcare system towards precision medicine and diagnostics technology is expected to boost the adoption of lung cancer genomic testing by healthcare facilities to help them make informed decisions.

Increased Awareness about Lung Cancer Genomic Testing Drives the Market Growth

The growing popularity of personalized medicine in the healthcare industry is expected to transform the way diseases such as lung cancer are being treated in healthcare facilities. Personalized medicine involves the study of cells obtained from biopsy and observing if there are any genetic mutations that can be linked with the cancer suffering patient. As certain chemotherapy drugs are either more or less effective than the others with specific mutations, genomic testing or molecular analysis can be used to determine which therapies can benefit an individual suffering from cancer. Genetic information obtained through genomic testing is useful to predict the chances if there are chances of cancer returning to the human body and make other important decisions about surgery or radiation therapy. Samples obtained from people with lung cancer are checked by studying the genetic mutations known to be vital in the development of the disease. Treatment can be personalized, which can prove to be useful for patients and increase the effectiveness of treatment. Therefore, increased awareness about personalized medicine and the benefits obtained from genomic testing is expected to accelerate the global lung cancer genomic testing market growth over the forecast period.

High Prevalence of Lung Cancer Boosts the Market Growth

The rising prevalence of cancer, increase in per capita income of consumers, and the large number of patients undergoing screening and treatment are increasing the demand for lung cancer genomic testing services worldwide. Lung cancer, including both small cell and non-small cell, is one of the most common kinds of cancer. According to The American Cancer Society, the estimates for lung cancer in the United States in 2022 are about 236,740 new cases of lung cancer and about 130,180 deaths from lung cancer. They generally occur in the old age population and in the people who smoke on a daily basis. Also, according to World Health Organization, cancer is the leading cause of death and accounted for nearly 10 million deaths in 2020, with which lung cancer death cases were 1.80 million across the globe. Therefore, there is a massive demand for technologies that can lower cancer incidence and mortality rate, and the reliability and benefits of genomic testing are expected to propel global lung cancer genomic testing market growth over the next five years.


DOWNLOAD FREE SAMPLE REPORT

Market Segmentation

The global lung cancer genomic testing market is segmented into component, technology, panel type, sample type, end user, regional distribution, and competitive landscape. Based on component, the market is divided into products v/s services. Based on technology, the market is divided into next generation sequencing, polymerase chain reactions, fluorescence in situ hybridization (FISH)/in situ hybridization (ISH), and others. Based on panel type, the market is divided into single panel v/s multi-gene panel. Based on sample type, the market is divided into tissue biopsy v/s liquid biopsy. Based on end user, the market is divided into academic & research institutions, hospitals & clinics, diagnostic laboratories, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region. In terms of country, the United States is expected to be a lucrative market due to the early adoption of advanced technologies by the healthcare sector and the high prevalence of lung cancer in the country.

Market Players

Qiagen NV, Agilent Technologies, Inc., Thermo Fischer Scientific, Inc., Quest Diagnostics, Inc., Laboratory Corporation of America Holdings, Centogene N.V., CeGaT GmbH, Illumina, Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Inc., CD Genomics, NeoGenomics Laboratories, OPKO Health, Inc., OncoDNA, Admera Health are the major market players operating in the global lung cancer genomic testing market.

Attribute

Details

Base Year

2021

Historic Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Component

·         Technology

·         Panel Type

·         Sample Type

·         End User

Regional scope

North America; Asia Pacific; Europe; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Denmark; Netherlands; Brazil; Argentina; Columbia; South Africa; UAE; Saudi Arabia; Turkey

Key companies profiled

Qiagen NV, Agilent Technologies, Inc., Thermo Fischer Scientific, Inc., Quest Diagnostics, Inc., Laboratory Corporation of America Holdings, Centogene N.V., CeGaT GmbH, Illumina, Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Inc., CD Genomics, NeoGenomics Laboratories, OPKO Health, Inc., OncoDNA, Admera Health

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, global lung cancer genomic testing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Lung Cancer Genomic Testing Market, By Component:
    • Products
    • Services
  • Lung Cancer Genomic Testing Market, By Technology:
    • Next Generation Sequencing
    • Polymerase Chain Reactions
    • Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
    • Others
  • Lung Cancer Genomic Testing Market, By Panel Type:
    • Single Panel
    • Multi-Gene Panel
  • Lung Cancer Genomic Testing Market, By Sample Type:
    • Tissue Biopsy
    • Liquid Biopsy
  • Lung Cancer Genomic Testing Market, By End User:
    • Academic & Research Institutions
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Others
  • Lung Cancer Genomic Testing Market, By Region:
    • North America
      • United States
      • Mexico
      • Canada
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
    • Europe
      • Germany
      • France
      • United Kingdom
      • Spain
      • Italy
      • Denmark
      • Netherlands
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa

§  South Africa

§  UAE

§  Saudi Arabia

§  Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global lung cancer genomic testing market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global lung cancer genomic testing market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Service Overview

2.    Research Methodology

3.    Executive Summary

4.    Impact of COVID-19 on Global Lung Cancer Genomic Testing Market

5.    Voice of Customer

5.1.  Lung Cancer Prevalence, By Type

5.2.  Lung Cancer Prevalence, By Gender

5.3.  Lung Cancer Prevalence, By Age Group

5.4.  Lung Cancer Prevalence, By Region

5.5.  Causes of Lung Cancer

6.    Clinical Trial Analysis

7.    Patent Analysis

8.    Global Lung Cancer Genomic Testing Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Component (Products v/s Services)

8.2.2.     By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)

8.2.3.     By Panel Type (Single Panel v/s Multi-Gene Panel)

8.2.4.     By Sample Type (Tissue Biopsy v/s Liquid Biopsy)

8.2.5.     By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)

8.2.6.     By Company (2021)

8.2.7.     By Region

8.3.  Product Market Map

9.    North America Lung Cancer Genomic Testing Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Component

9.2.2.     By Technology

9.2.3.     By Panel Type

9.2.4.     By Sample Type

9.2.5.     By End User

9.2.6.     By Country

9.3.  Policy & Regulatory Landscape

9.4.  North America: Country Analysis

9.4.1.     United States Lung Cancer Genomic Testing Market Outlook

9.4.1.1.         Market Size & Forecast

9.4.1.1.1.             By Value

9.4.1.2.         Market Share & Forecast

9.4.1.2.1.             By Component

9.4.1.2.2.             By Technology

9.4.1.2.3.             By Panel Type

9.4.1.2.4.             By Sample Type

9.4.1.2.5.             By End User

9.4.2.     Mexico Lung Cancer Genomic Testing Market Outlook

9.4.2.1.         Market Size & Forecast

9.4.2.1.1.             By Value

9.4.2.2.         Market Share & Forecast

9.4.2.2.1.             By Component

9.4.2.2.2.             By Technology

9.4.2.2.3.             By Panel Type

9.4.2.2.4.             By Sample Type

9.4.2.2.5.             By End User

9.4.3.     Canada Lung Cancer Genomic Testing Market Outlook

9.4.3.1.         Market Size & Forecast

9.4.3.1.1.             By Value

9.4.3.2.         Market Share & Forecast

9.4.3.2.1.             By Component

9.4.3.2.2.             By Technology

9.4.3.2.3.             By Panel Type

9.4.3.2.4.             By Sample Type

9.4.3.2.5.             By End User

10.  Europe Lung Cancer Genomic Testing Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Component

10.2.2.  By Technology

10.2.3.  By Panel Type

10.2.4.  By Sample Type

10.2.5.  By End User

10.2.6.  By Country

10.3.              Policy & Regulatory Landscape

10.4.              Europe: Country Analysis

10.4.1.  France Lung Cancer Genomic Testing Market Outlook

10.4.1.1.      Market Size & Forecast

10.4.1.1.1.           By Value

10.4.1.2.      Market Share & Forecast

10.4.1.2.1.           By Component

10.4.1.2.2.           By Technology

10.4.1.2.3.           By Panel Type

10.4.1.2.4.           By Sample Type

10.4.1.2.5.           By End User

10.4.2.  Germany Lung Cancer Genomic Testing Market Outlook

10.4.2.1.      Market Size & Forecast

10.4.2.1.1.           By Value

10.4.2.2.      Market Share & Forecast

10.4.2.2.1.           By Component

10.4.2.2.2.           By Technology

10.4.2.2.3.           By Panel Type

10.4.2.2.4.           By Sample Type

10.4.2.2.5.           By End User

10.4.3.  United Kingdom Lung Cancer Genomic Testing Market Outlook

10.4.3.1.      Market Size & Forecast

10.4.3.1.1.           By Value

10.4.3.2.      Market Share & Forecast

10.4.3.2.1.           By Component

10.4.3.2.2.           By Technology

10.4.3.2.3.           By Panel Type

10.4.3.2.4.           By Sample Type

10.4.3.2.5.           By End User

10.4.4.  Italy Lung Cancer Genomic Testing Market Outlook

10.4.4.1.      Market Size & Forecast

10.4.4.1.1.           By Value

10.4.4.2.      Market Share & Forecast

10.4.4.2.1.           By Component

10.4.4.2.2.           By Technology

10.4.4.2.3.           By Panel Type

10.4.4.2.4.           By Sample Type

10.4.4.2.5.           By End User

10.4.5.  Spain Lung Cancer Genomic Testing Market Outlook

10.4.5.1.      Market Size & Forecast

10.4.5.1.1.           By Value

10.4.5.2.      Market Share & Forecast

10.4.5.2.1.           By Component

10.4.5.2.2.           By Technology

10.4.5.2.3.           By Panel Type

10.4.5.2.4.           By Sample Type

10.4.5.2.5.           By End User

10.4.6.  Denmark Lung Cancer Genomic Testing Market Outlook

10.4.6.1.      Market Size & Forecast

10.4.6.1.1.           By Value

10.4.6.2.      Market Share & Forecast

10.4.6.2.1.           By Component

10.4.6.2.2.           By Technology

10.4.6.2.3.           By Panel Type

10.4.6.2.4.           By Sample Type

10.4.6.2.5.           By End User

10.4.7.  Netherlands Lung Cancer Genomic Testing Market Outlook

10.4.7.1.      Market Size & Forecast

10.4.7.1.1.           By Value

10.4.7.2.      Market Share & Forecast

10.4.7.2.1.           By Component

10.4.7.2.2.           By Technology

10.4.7.2.3.           By Panel Type

10.4.7.2.4.           By Sample Type

10.4.7.2.5.           By End User

11.  Asia-Pacific Lung Cancer Genomic Testing Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Component

11.2.2.  By Technology

11.2.3.  By Panel Type

11.2.4.  By Sample Type

11.2.5.  By End User

11.2.6.  By Country

11.3.              Policy & Regulatory Landscape

11.4.              Asia-Pacific: Country Analysis

11.4.1.  China Lung Cancer Genomic Testing Market Outlook

11.4.1.1.      Market Size & Forecast

11.4.1.1.1.           By Value

11.4.1.2.      Market Share & Forecast

11.4.1.2.1.           By Component

11.4.1.2.2.           By Technology

11.4.1.2.3.           By Panel Type

11.4.1.2.4.           By Sample Type

11.4.1.2.5.           By End User

11.4.2.  India Lung Cancer Genomic Testing Market Outlook

11.4.2.1.      Market Size & Forecast

11.4.2.1.1.           By Value

11.4.2.2.      Market Share & Forecast

11.4.2.2.1.           By Component

11.4.2.2.2.           By Technology

11.4.2.2.3.           By Panel Type

11.4.2.2.4.           By Sample Type

11.4.2.2.5.           By End User

11.4.3.  South Korea Lung Cancer Genomic Testing Market Outlook

11.4.3.1.      Market Size & Forecast

11.4.3.1.1.           By Value

11.4.3.2.      Market Share & Forecast

11.4.3.2.1.           By Component

11.4.3.2.2.           By Technology

11.4.3.2.3.           By Panel Type

11.4.3.2.4.           By Sample Type

11.4.3.2.5.           By End User

11.4.4.  Japan Lung Cancer Genomic Testing Market Outlook

11.4.4.1.